Human RANKL/OPGL/TNFSF11 (CD254) (Fc Tag) recombinant protein

Human RANKL/OPGL/TNFSF11 (CD254) (Fc Tag) recombinant protein

• DataSheet
• Material Safety Data Sheets (MSDS)

Tumor necrosis factor ligand superfamily member 11, also known as Receptor activator of nuclear factor kappa-B ligand, Osteoprotegerin ligand, TNFSF11, RANKL, TRANCE, OPGL and CD254, is a single-pass type II membrane protein which belongs to the tumor necrosis factor family. The receptor activator of nuclear factor-kappaB ligand (RANKL), its cognate receptor RANK, and its natural decoy receptor osteoprotegerin have been identified as the final effector molecules of osteoclastic bone resorption. RANK and RANKL are key regulators of bone remodeling and regulate T cell/dendritic cell communications, and lymph node formation. Moreover, RANKL and RANK are expressed in mammary gland epithelial cells and control the development of a lactating mammary gland during pregnancy. Genetically, RANKL and RANK are essential for the development and activation of osteoclasts and bone loss in response to virtually all triggers tested. Inhibition of RANKL function via the natural decoy receptor osteoprotegerin (OPG, TNFRSF11B) prevents bone loss in postmenopausal osteoporosis and cancer metastases. Importantly, RANKL appears to be the pathogenetic principle that causes bone and cartilage destruction in arthritis. RANK-RANKL signaling not only activates a variety of downstream signaling pathways required for osteoclast development, but crosstalk with other signaling pathways also fine-tunes bone homeostasis both in normal physiology and disease. In addition, RANKL and RANK have essential roles in lymph node formation, establishment of the thymic microenvironment, and development of a lactating mammary gland during pregnancy.

Tumor necrosis factor ligand superfamily member 11

CD254; OPGL; ODF; SODF; RANKL; LY109L; TRANCE; RP11-86N24.2; HRANKL2; OPG; OPTB2; TNFSF11

O14788

TNFSF11; OPGL; RANKL; TRANCE

Human Cells

A DNA sequence encoding the human TNFSF11 (O14788-2) (Gly 63-Asp 244) was expressed with the Fc region of rabbit IgG at the N-terminus.

Human

The recombinant human TNFSF11 comprises 431 amino acids and has a predicted molecular mass of 47.9 kDa. The apparent molecular mass of the protein is approximately 56 kDa in SDS-PAGE under reducing conditions due to glycosylation.

> 85 % as determined by SDS-PAGE

1. Immobilized human rFc2L3-TNFSF11 at 10μg/mL (100μL/well) can bind biotinylated human TNFRSF11B-His (Cat:500115), The EC₅₀ of biotinylated human TNFRSF11B-His (Cat:500115) is 5.7-13.4ng/ml.
2. The bioactivity of hRANKL was determined by measuring the ability of hRANKL to induce TRAP activity in Raw 264.7 cells. The ED₅₀ for this effect is 1.5-7.5ng/mL.